Markets

Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13

Oct 9, 2026 · 07:22 AM ET· updated 1h ago

Congress is taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed pharmacokinetic (PK) analyses

Why It Matters

Seaport will show early human test results for a new drug called GlyphAgo. When a company shares new science data, watch if doctors and scientists seem interested in it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SPTX18.18

+0.25 (+1.39%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.